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Nitric oxide (NO) plays an important role in physiological regulation of the airways. The monitoring of airway 
inflammation has being observed in bronchial asthma directly, by sputum examination, and indirectly, by, 
measurements in peripheral blood. To investigate the diagnostic value of these two methods, we compared NO 
metabolites in induced sputum and serum obtained in patients with asthma and control subjects. Hypertonic saline 
induced sputum and serum were,obtained in 13 patients with asthma and 10 control subjects. NO metabolite level 
was assayed by using modified’ ‘Griess reaction. Eosinophil cationic protein (ECP) was measured by 
fluoroimmunoassay, and detected ‘interleukin (IL)-5 by a sandwich ELISA. The accuracy of the tests was 
measured by plotting the data in receiver operating characteristic (ROC) curves and comparing the area under the. 
curve for NO metabolites. Asthmatic patients, compared with control subjects, had significantly higher NO: 
metabolites in induced sputum (1252.5+203.3.‘moll-’ vs. 557.2+ 101.5 mol l-l, PcO.01) but not in serum. IL-5 in 
induced sputum was detected more frequently in patients with asthma than in control subjects [l l/13 (84.6%) vs. 
l/l0 (lo%), P<O.Ol]. Asthmatic patients, compared with control subjects, had significantly higher ECP 
concentration in induced sputum (1270.0 k 197.9 g 1 vs. 1546 + 47.4 g l- ‘, P<O,Ol). There were significant positive 
correlations between NO metabolites in induced sputum and eosinophils, ECP in induced sputum (r=0.58 P< ti.05; 
r=0.64, P<O.Ol) in patients with asthma but not in serum. The area under the ROC curve showed that NO 
metabolites in induced sputum (0.78) are more accurate marker than NO metabolites in serum (0.53) (PcO.05). 
These findings suggest that NO metabolites in induced sputum is a more valuable indicator to monitor asthmatic 
airway inflammation than those in serum. 
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Introduction 
Nitric oxide (NO) plays an important role in physiological 
regulation of the airways and is produced in increased 
amounts ‘in asthma (1). NO may amplify and perpetuate 
allergic inflammation by selective inhibition of helper T 
lymphocytes (Thl) which secrete interferon (IFN)-y 
and in turn suppress the proliferation of Th2 lympho- 
cytes (1,2). Eosinophilic inflammation in asthma is 
driven by Th2 lymphocytes which secrete interleukin 
(IL)-5 (1). 
Previous studies have demonstrated the airway inflam- 
mation in bronchial asthma directly by bronchoscopic 
biopsies (3-5), bronchoalveolar lavages (6-7), or sputum 
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Serum concentrations of NO are elevated in, patients 
with cirrhosis (16). This condition may result from 
excessive nitric oxide generated by the inducible enzyme. 
NO, which is produced by a variety of cells in the airways, 
probably plays a systemically physiological role in asthma. 
However, there are no studies examining whether NO 
production within the airways would be reflected systemi- 
cally. Therefore the role of NO in blood in patients with 
asthma should be clarified. To the best of our knowledge, 
there has been no published data comparing NO 
metabolite level in induced sputum with those in serum. 
To investigate the diagnostic value of sputum and serum 
NO as marker of airway inflammation, we compared the 
level of NO metabolites in induced sputum and serum 
collected in asthmatic patients and control subjects. 
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examinations (8,9), and indirectly by measurements in 
peripheral blood (10,ll). 
A recent report (12) has shown that the concentration of 
NO derivatives is high in induced sputum in patients with 
asthma. Increased NO production in the airway has been 
reported in exhaled air of animals and asthmatic patients 
(13-15). 
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Patients and methods 
STUDY SUBJECTS 
Thirteen patients with asthma were recruited for this study 
from the Division of Allergy, Department of Internal 
Medicine, Chonnam University Hospital, Korea between 
March and December, 1997. The diagnoses of asthma were 
established in the patients by ‘their symptoms of recurrent 
episodic wheezing, cough, and/or dyspnoea, accompanied 
either by’methacholine airway hyper-responsiveness, with a 
baseline methacholine PC2018 mg ml-’ (eight patients) or 
by a significant improvement in forced expiratory volume in 
1 set (FEVi) (15%) following anti-asthma therapy (five 
patients). Seven patients were atopic. Eleven patients were 
treated with regular inhaled corticosteroids and &agonists 
when needed, while two only used /&agonists when needed. 
No subject had respiratory infection for 4 weeks prior to 
the study. Ten control subjects, who were matched for age 
and sex, and volunteered for this study, had no history of 
any respiratory symptoms and had a FEVi >75% pre- 
dicted, a ratio of FEVi to forced vital capacity (FVC) 
> 75%, and a normal methacholine airway responsiveness 
[provocation concentration of methacholine producing a 
20% fall of FEVi (Pc20) > 16 mg]. The study was approved 
by Chonnam University Hospital Research Committee and 
all subjects signed the informed consent forms. 
STUDY DESIGN 
Airway inflammatory markers in hypertonic saline-induced 
sputum and serum were measured in patients with asthma 
and compared to those in control subjects. A questionnaire 
for symptoms and medications was given and a spirometry 
was also performed. Induced sputum and serum was 
collected, and skin prick tests and methacholine provoca- 
tion tests were done. Clinical severity of asthma was 
classified by the method of the International Consensus 
Report (17). All measurements in sputum and serum were 
obtained by a person blind to the clinical characteristics of 
subjects. 
Methods 
PULMONARY FUNCTION TESTING 
Spirometry was performed according to American Thoracic 
Society standards (18) using SensorMedics 2200 spirometer 
(Cardiopulmonary Care Company TM, Yorba Linda, Cali- 
fornia, U.S.A.). The representative values for FVC and 
FEVi were selected according to International Thoracic 
Society criteria (19) and the reference values were taken 
from the reports by Choi et al. (20) and by Kim et al. (21). 
NONSPECIFIC AIRWAY HYPER- 
RESPONSIVENESS 
Methacholine challenge tests were carried out by the 
method described by Chai et al. (22) and the results were 
expressed as Pc20 [Pc20 FEVi was defined as a provoking 
dose of methacholine causing 20% fall in FEV, (forced 
expiratory volume in 1 set)] in non-cumulative units. 
ALLERGY SKIN TEST 
Allergy skin prick tests were performed using 55 common 
allergen extracts. The results were read 15 min after the 
prick. The wheal and erythema size were measured, as 
maximum diameter and vertical length at the mid portion 
of maximum length, and presented as the mean value of the 
maximum diameter. Atopy is defined by one or more 
positive allergy skin prick tests. 
SPUTUM INDUCTION AND PROCESSING 
The sputum induction and examination were performed as 
described by Fahy et al. (23) and Popov et al. (24) with 
modification. All subjects were premeditated with two puffs 
of inhaled salbutamol (200 pg). Subjects inhaled 3% 
hypertonic saline solution aerosols generated by an ultra- 
sonic nebulizer (NE-U03, OMRON Co., Tokyo, Japan) 
with maximum output of 0.154.3 ml min-’ and mass 
median aerodynamic diameter of 4.5 pm. Hypertonic saline 
was inhaled for 20-30 min according to the severity of 
asthma until an adequate volume of sputum expectorated. 
They were instructed to cough the sputum into a sterile 
plastic container. The volumes of samples and duration of 
sputum induction were recorded. FEVi was measured 
before, during and after induction of sputum. Sputum 
induction was stopped in each subject with a fall of the 
FEVi>lS%. 
Sputum was selected from saliva and processed within 
2 h. Sputum was treated by adding equal volumes of 0.1% 
dithiothreitol (Sputalysin 10%; Gibco BRL, Grand Island, 
NY, U.S.A.) followed by equal volumes of Dulbecco’s 
phosphate buffered saline (D-PBS). The sample was then 
mixed gently and placed in a shaking water bath at 37°C for 
15 min to ensure complete homogenization. The sample 
was removed from the water bath periodically for further 
brief gentle mixing. The suspension was filtered through a 
gauze (1 mm pore size), the filtrate was centrifuged at 
1500 rpm for 10 min and the supernatant was aspirated and 
stored in Eppendorf tubes at -70°C for later assay. The 
cell pellet was resuspended in D-PBS, 1000 ~1 and total 
non-squamous cells were counted in a modified Neubauer 
hemocytometer (AO, New York, U.S.A.). The cell suspen- 
sion was adjusted to 0.5 x lo5 ml-‘, and then 50 ~1 of cell 
suspension was placed into cups of Sakura cytocentrifuge 
(Model CF-127, Tokyo, Japan), and two coded cytospins 
were prepared at 600 rpm at 5 min, air dried and stained by 
Diff-Quick@ (Kookje Scientific Products, Tokyo, Japan) 
stain. Cell differentials of 400 non-squamous cells were 
performed by Diff-Quick stain on slides by two investiga- 
tors who did not know the subject’s history, and results 
were expressed as a percentage of the total non-squamous 
cell count. 
914 A.-S. JANG AND I.-S. CHOI 
BLOOD SAMPLING IL-5 AND ECP MEASUREMENT 
Venous blood was collected in tubes containing 50 ml 
ethylenediaminetetraacetic acid (K3 Vacutainer BD, 
Rutherfold, NJ, U.S.A.) before sputum induction and 
differential white blood cell count was obtained with use of 
a Coulter STKS instrument (Coulter Corp., Hialeah, FL, 
U.S.A.). Serum was collected after blood coagulation for 
1 h at room temperature. It was centrifuged at 20°C at 
1500 rpm for 10 min and stored in Eppendorf tubes at 
-70°C for later assay. 
IL-5 was measured by quantitative sandwich enzyme 
immunoassay (QuantikineTM; R&D Systems, Inc., Min- 
neapolis, U.S.A.), as described by Dickason et al. (26). The 
concentration of ECP in 400 ~1 in the supernatant of in- 
duced sputum and serum was determined using fluoroim- 
munoassay (UniCAP system, Pharmacia AB, Uppsala, 
Sweden). Samples were analysed in duplicate. The limit of 
detection for IL-5 and ECP assays were 3 pg ml-’ and 
2.0 pg l- ‘, respectively. 
NITRITE AND NITRATE ASSAY , 
Nitrite production was calorimetrically quantified after the 
Griess reaction as described by Greenberg et al. (25). One 
hundred ~1 of induced sputum supematant and serum or 
standard were mixed with an equal volume of Griess 
reagent (1% sulfanilamide/O. 1% naphthylethyllene dihy- 
drochloride/2.5% phosphoric acid, Sigma Chemical Co., 
Sigma Chemical Co., St Louis, MO, U.S.A.) in duplicate 
microtitre wells at room temperature. Chromophore 
absorbance at 540 nm was determined. Nitrite concentra- 
tion was calculated using sodium nitrite (Sigma Chemical 
Co., Sigma Chemical Co., St Louis, MO, U.S.A.) as a 
standard. 
For assay of nitrate of samples, 200 ~1 of sputum 
supernatant and serum or standard containing 100 ~1 of 
200 mM ammonium formate (including 100 mM HEPES, 
Sigma Chemical Co.) was reduced to nitrite at 37°C for 1 h 
by adding 100 1 nitrate reductase [E. coli (ATCC25922), 
American Type Collection, Rockville, MD, U.S.A.], 
followed by centrifugation to precipitate non-reacting E. 
coli for 5 min, and then the nitrite was quantified as 
described above. The interassay and intraassay variablity 
are, respectively, f 4% and k 5% for NO metabolites. 
STATISTICAL ANALYSIS 
All data were analysed using the SPSS version 7.5 for 
Windows (Chicago, IL, U.S.A.). Data are expressed as 
mean + SEM. Comparison of variables was performed using 
Student’s t-test and the Mann-Whitney U-test. Pearson’s 
correlations and Spearman’s correlations were used to 
assess relationships between variables. Because the vari- 
ables had a continuous scale of values, where the selection 
of a cutoff point was arbitrary, we determined the 
diagnostic accuracy of sputum and serum NO metabolites 
by generating a receiver operating characteristic (ROC) 
curve (27). The area under the curves (AUCs) were 
compared by the method of Hanley and McNeil (28). A 
P-value of co.05 was considered significant. 
Results 
Subject characteristics are given in Table 1. All subjects 
tolerated the sputum induction procedure well. Asthmatic 
patients had significant lower FEVi and FEVi/FVC than 
those of control subjects. 
TABLE 1. Characteristics of patients with asthma 
Patient 
No. 
Age Sex Duration 
W 
Ig E 
(IU ml-‘) 
FEVi 
(“A pred) 
Pc20 M 
(mg ml-‘) 
1 24 F 15 266.9 78.8 NA 
2 45 M 0.6 153.7 60.0 0.128 
3 47 F 2 188.5 50.3 0.5801 
4 39 M 5 NA 55.5 NA 
5 38 F 1 30.1 58.0 0.9749 
6 24 M 1 82.2 87.1 0.5600 
7 26 M 5 30.1 76.2 0.1200 
8 46 M 2 876.0 59.3 4.4820 
9 54 F 3 4840.0 54.4 0.9279 
10 40 M 1 1415.0 62.8 4.5140 
11 59 M 1 1410.0 49.3 NA 
12 51 F 10 260.0 64.5 NA 
13 49 M 7 413.0 96.5 NA 
Pc20 M:Pc20 methacholine [PC20 FEVr was defined as a provoking dose of methacholine causing 20% fall in FEV, (forced 
expiratory volume in one second)]; NA: no attributable. 
2500 P < 0.01 n.5. 
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FIG. 1. Concentration of NO metabolites level in induced 
sputum and serum in asthmatic patients (A) and control 
subjects (C). Horizontal bars: mean values. n : sputum; 
0: serum. 
INFLAMMATORY CELLS 
The sputum contained less than 30% squamous epithelial 
cells, and had greater than 85% of cell viability. The 
proportion of eosinophils and neutrophils in induced 
sputum were significantly higher in patients with asthma 
than in control subjects (eosinophils: 48.6+ 54% vs. 
1.8+0.2%, PcO.01; neutrophils: 18.5+2.4% vs. 
9.4f 1.9%, P<O.Ol), whereas the proportion of macro- 
phages was lower (25.9+5.1% vs. 84.0+ 1.7%, P<O.Ol). 
The percentage of eosinophils is high due to patients 
selection including acute exacerbated patients. No signifi- 
cant differences were noted between asthmatic patients and 
control subjects in either total cell count or the absolute or 
relative numbers of lymphocytes and epithelial cells in 
induced sputum. The count of eosinophils in blood was 
significantly higher in patients with asthma than in control 
subjects (1069.0+440.5 ~1~’ vs. 124.4k31.9 ,ul-‘, 
P<O.Ol). 
NITRIC OXIDE METABOLITES IN PATIENTS WITH ASTHMA 915 
NO METABOLITES, IL-5 AND ECP 
The sputum from patients with asthma contained higher 
levels of NO metabolites (1252.5f203.3 pmol 1-l W. 
557,2f 101.5 pmol l-l, P<O.Ol; Fig. 1) than in serum. The 
AUC for each test revealed that the level of NO metabolites 
in induced sputum (0.78) was more sensitive and specific 
than the determination of serum NO metabolites (0.53) in 
differentiation of patients with asthma from control 
subjects (Fig. 2). IL-5 in induced sputum was detected 
more frequently in patients with asthma than in control 
subjects [11/13 (84.6%) vs. l/l0 (lo%), P<O.Ol)]. Asth- 
matic patients had a significantly higher ECP concentration 
in induced sputum (1270.0f 197.9 pg 1 vs. 154.6k47.4 /*g 
l-‘, PcO.01) compared with control subjects. 
RELATIONSHIP BETWEEN NO 
METABOLITES AND PHYSIOLOGICAL 
VARIABLES 
NO metabolites in induced sputum were positively corre- 
lated with ECP in induced sputum (r=0.64, PcO.01; 
Fig. 3(a)). There was a significantly positive correlation 
between FEVJFVC and ECP in induced sputum (r=0.59, 
P<O.Ol). The level of NO metabolites in induced sputum 
tended to have positive correlation with FEVJFVC 
(r=0.53, P=O.O6; Fig. 3(b)). However, there was no 
correlation between serum NO metabolites and lung 
function. No correlation was noted between inflammatory 
markers in induced sputum, serum and atopy score and 
airway hyper-responsiveness. 
Discussion 
The results of the current study show that NO metabolites 
in induced sputum compared with those in serum is a more 
useful, practical indicator in monitoring asthmatic airway 
inflammation. 
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@IG. 2. NO metabolites in induced sputum and serum ROC curve. Plots that lie farthest to the ‘northwest’ represent more 
accurate values. -O-: serum, -w-: sputum. 
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FIG. 3(a) Correlations between NO metabolites level in 
induced sputum and ECP in induced sputum in asthmatic 
patients (r=0.64; P=O.Ol). (b) Correlations between NO 
metabolites level in induced sputum and FEVi/FVC in 
asthmatic patients (r=0.53; P=O.O6). 
Previous studies have demonstrated the airway inflam- 
mation in bronchial asthma directly by bronchoscopic 
biopsies (3-5), bronchoalveolar lavages (6-7) and sputum 
examinations (8,9), and indirectly by measurements in 
peripheral blood (10,ll). This study is the first comparison 
of diagnostic accuracy between NO metabolites measured 
in induced sputum and peripheral blood samples. In the 
present study, higher levels of NO metabolites were shown 
in patients with asthma than in control subjects in induced 
sputum but not in serum. The AUC for each test revealed 
that the level of NO metabolites in induced sputum was 
more sensitive and specific than the determinations of 
serum NO metabolites in differentiation of patients with 
asthma from control subjects. These results imply that NO 
contributes to inflammation limited to trachea-bronchial 
tree. 
NO may amplify allergic inflammation by selective 
inhibition of T lymphocytes that secrete IFN-y (Thl), 
which suppresses the proliferation of Th2 cells (28,34). In 
this study, although IL-5 not significantly correlated with 
NO metabolites, IL-5 significantly detected in the sputum 
of asthmatic subjects than in control subjects, suggesting 
that release of NO may contribute to allergic inflammation. 
NO is endogenously derived from the amino acid L- 
arginine by three forms of the NO synthases (NOS). Two 
constitutive NOS are involved in physiological regulation 
of airway function, and inducible NOS is involved in 
inflammatory disease of the airways (1). Immunohistologi- 
cal studies have identified the presence of all three isoforms 
in human airways (29). 
Several authors reported that NO in exhaled air 
increased in asthmatic subjects (30-31). High exhaled NO 
concentrations in asthmatic patients may reflect induc- 
tion of NOS. Measurement of exhaled NO concentration 
may be clinically useful in detection and manage- 
ment of cytokine mediated inflammatory lung disorders 
(32). 
Kanazawa et al. (12) reported that measurement of NO 
derivatives in induced sputum may be useful for assessing 
allergic inflammation in airways. NO levels in induced 
sputum were significantly correlated with percentages of 
shedding epithelial cells. NO generated by inducible NOS 
(iNOS) in airway epithelial cells combined avidly with 
superoxide anion generated by inflammatory cells in 
airways to form peroxynitrite, which may have inflamma- 
tory effects directly and through the generation of toxic 
hydroxyl radicals that may contribute to airway epithelial 
shedding in asthma (12). NO may indirectly exacerbate the 
airway inflammatory response by inducing shedding of 
epithelial cells (12), because damage to airway epithelial 
cells may occur even in patients with relatively mild asthma, 
thereby exposing afferent nerve endings (3). We (33) 
reported that the level of NO metabolites were increased 
in the trachea-bronchial secretion of asthmatic subjects and 
was paralleled by severity of asthma. Measurement of NO 
metabolites in induced sputum may be used for monitoring 
the degree of airway inflammation in asthmatics. However, 
in contrast to a previous report (12) this study did not 
demonstrate a significant correlation between epithelial 
cells and NO metabolites. However, we showed that the 
proportion of eosinophils positively correlated with NO 
metabolites, suggesting a possibility that there is another 
source which releases NO metabolites. It has been reported 
that cells potentially capable of generating NO in the lungs 
include macrophages, neutrophils, mast cells, nonadrener- 
gic inhibitory neurons, fibroblasts, vascular smooth muscle 
cells, pulmonary artery and venous endothelial cells and 
pulmonary epithelial cells (32-33). Further study will be 
needed to evaluate the role of NO metabolites in induced 
sputum in asthma. 
Serum concentrations of NO are elevated in patients with 
cirrhosis (16). This condition may result from excessive 
nitric oxide generated by the inducible enzyme. We 
evaluated whether NO had a probability of systemically 
playing a physiological role in asthma. In this study we 
didn’t find that NO levels in serum were increased. These 
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results imply that NO has an effect on inflammation limited 
to the respiratory tract in asthma. 
In accordance with a previous report (12), we found that 
NO metabolites in induced sputum tended to correlate with 
airway obstruction (FEVi/FVC) but not in serum. There- 
fore induced sputum NO metabolites could serve as a useful 
marker for monitoring disease activity in asthmatic 
patients. We did not find a correlation between NO 
metabolites in induced sputum and serum, and non-specific 
airway hyper-responsiveness. The significance of increased 
NO metabolites in induced sputum needs to be evaluated in 
such a population with correlations to symptoms and 
treatment. 
We conclude that NO metabolites in induced sputum 
have a more valuable diagnostic value than those in serum 
in monitoring airway inflammation in asthma. 
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